Neuland Laboratories Limited
NEULANDLAB · 524558 · Healthcare · Pharmaceuticals
- Market cap
- Rs 24,872 Cr
- P/E
- 49.69x
- P/B
- 13.27x
- 52W high / low
- Rs 24,225 / Rs 11,500
About Neuland Laboratories
Neuland Laboratories Limited is listed on the NSE under the symbol NEULANDLAB and on the BSE under scrip code 524558. It is classified in the Healthcare sector, industry: Pharmaceuticals. It is a constituent of BSE 500, NIFTY 500 and NIFTY Smallcap 250. The company listed on 13 Oct 2008 and has a face value of Rs 10.
The latest available end-of-day price is Rs 19,280 (−3.46% on the day), for a market capitalisation of Rs 24,872 Cr. Trailing P/E is 49.69x and price-to-book is 13.27x. The 52-week range is Rs 11,500 to Rs 24,225. The latest price is 61% of the way from the 52-week low to the 52-week high.
Against the 16-company comparison set from the official BSE basic industry Pharmaceuticals, its market capitalisation is 0.3 times the peer median of Rs 93,249 Cr, and its P/E of 49.69x compares with a peer median of 37.86x. The comparison set is chosen mechanically from the exchange classification; it is not a ranking.
Latest annual results
For FY26 (year ended 31 Mar 2026), Neuland Laboratories Limited reported revenue of Rs 2,023 Cr and net profit of Rs 364 Cr, with a net margin of 17.99% and earnings per share of Rs 283.71 (consolidated statements).
Year-on-year change: revenue +37.12%; net profit +39.94%; EPS +39.94%. Three-year compound annual growth rate: revenue +19.57%; net profit +30.56%.
At the same date the balance sheet shows total assets of Rs 2,930 Cr, shareholders' equity of Rs 1,874 Cr, total debt of Rs 197 Cr, cash of Rs 76.7 Cr, a debt-to-equity ratio of 0.10 and operating cash flow of Rs 347 Cr.
On a trailing-twelve-month basis the filings add up to revenue of Rs 2,372 Cr, net income of Rs 498 Cr and a net margin of 20.99%.
Shareholding pattern
In the shareholding pattern for 30 Sept 2026, Neuland Laboratories Limited's ownership is split: promoters 32.26%; foreign institutional investors (FIIs) 21.93%; domestic institutional investors (DIIs) 16.26%; retail and other shareholders 29.55%.
Compared with the filing for 30 Jun 2026: promoter holding −0.36 percentage points; FII holding +0.85 percentage points; DII holding −0.25 percentage points.
The same filing lists reported promoter pledge of 2.32% and 49,741 shareholders on record.
Recent filings and corporate actions
104 BSE corporate announcements were filed by Neuland Laboratories Limited in the past twelve months; the most frequent category is "Company Update" (76). The most recent is "Intimation of Loss of Share Certificate(s)" (Others), filed on 29 Oct 2026.
The disclosed corporate-action timeline lists 5 entries: dividend (5). The latest is a dividend (Final Dividend - Rs. - 34.0000) with ex-date 24 Jul 2026.
Figures are raw disclosures from official NSE/BSE and SEBI filings plus mechanically computed ratios, restated in words. This is research data, not investment advice, a rating or a recommendation; DalalOS is not a SEBI-registered investment advisor.
More
Peer comparison
Official BSE basic industry: Pharmaceuticals. Limited to companies within a 0.1x–10x market-cap band.
Edit columns
| Torrent Pharmaceuticals Limited | Rs 4,580 | Rs 1,55,015 Cr | Rs 15,654 Cr | Rs 2,156 Cr | 73.16x | 27.30% |
| Laurus Labs Limited | Rs 2,244 | Rs 1,21,232 Cr | Rs 7,323 Cr | Rs 1,091 Cr | — | 22.38% |
| Zydus Lifesciences Limited | Rs 1,184.4 | Rs 1,18,203 Cr | Rs 29,052 Cr | Rs 4,593 Cr | 26.40x | 17.68% |
| Dr. Reddy's Laboratories Limited | Rs 1,345 | Rs 1,12,308 Cr | Rs 34,353 Cr | Rs 2,760 Cr | 40.02x | 7.84% |
| Cipla Limited | Rs 1,358 | Rs 1,09,706 Cr | Rs 28,855 Cr | Rs 2,854 Cr | 37.86x | 8.83% |
| Mankind Pharma Limited | Rs 2,469.3 | Rs 1,01,982 Cr | Rs 15,705 Cr | Rs 2,264 Cr | 45.45x | 14.78% |
| Aurobindo Pharma Limited | Rs 1,659.9 | Rs 95,511 Cr | Rs 35,625 Cr | Rs 3,711 Cr | 25.94x | 10.53% |
| Lupin Limited | Rs 1,989.9 | Rs 90,988 Cr | Rs 30,442 Cr | Rs 5,551 Cr | 16.44x | 27.89% |
| Glenmark Pharmaceuticals Limited | Rs 2,339 | Rs 66,007 Cr | Rs 18,236 Cr | Rs 1,798 Cr | 36.71x | 15.46% |
| Alkem Laboratories Limited | Rs 5,079 | Rs 60,719 Cr | Rs 15,681 Cr | Rs 2,204 Cr | 28.15x | 16.72% |
| Biocon Limited | Rs 351.9 | Rs 57,346 Cr | Rs 17,638 Cr | Rs 416 Cr | — | 1.78% |
| Abbott India Limited | Rs 26,145 | Rs 55,558 Cr | Rs 7,295 Cr | Rs 1,615 Cr | 34.41x | 35.85% |
| Gland Pharma Limited | Rs 3,074.5 | Rs 50,717 Cr | Rs 7,045 Cr | Rs 1,129 Cr | 44.88x | 11.57% |
| IPCA Laboratories Limited | Rs 1,926.2 | Rs 48,868 Cr | Rs 10,293 Cr | Rs 1,375 Cr | 37.31x | 17.45% |
| Ajanta Pharma Limited | Rs 3,459.7 | Rs 43,367 Cr | Rs 5,993 Cr | Rs 1,135 Cr | 38.09x | 27.19% |
| Neuland Laboratories LimitedThis company | Rs 19,280 | Rs 24,872 Cr | Rs 2,403 Cr | Rs 498 Cr | 49.69x | 23.59% |
| Median | Rs 2,356.65 | Rs 93,249 Cr | Rs 15,667 Cr | Rs 2,180 Cr | 37.86x | 17.57% |
Peers are selected mechanically from the official BSE industry hierarchy and current market-cap band. This is a comparison set, not a ranking or recommendation.
Companies related to Neuland Laboratories
Same official industry (Pharmaceuticals)
- Torrent Pharmaceuticals LimitedTORNTPHARM · Market cap Rs 1,55,015 Cr
- Laurus Labs LimitedLAURUSLABS · Market cap Rs 1,21,232 Cr
- Zydus Lifesciences LimitedZYDUSLIFE · Market cap Rs 1,18,203 Cr
- Dr. Reddy's Laboratories LimitedDRREDDY · Market cap Rs 1,12,308 Cr
- Cipla LimitedCIPLA · Market cap Rs 1,09,706 Cr
- Mankind Pharma LimitedMANKIND · Market cap Rs 1,01,982 Cr
- Aurobindo Pharma LimitedAUROPHARMA · Market cap Rs 95,511 Cr
- Lupin LimitedLUPIN · Market cap Rs 90,988 Cr
Other Healthcare companies of a similar market capitalisation
- Acutaas Chemicals LimitedACUTAAS · Market cap Rs 32,558 Cr
- Dr. Lal Path Labs Ltd.LALPATHLAB · Market cap Rs 32,040 Cr
- Sai Life Sciences LimitedSAILIFE · Market cap Rs 31,752 Cr
- Wockhardt LimitedWOCKPHARMA · Market cap Rs 31,151 Cr
- Piramal Pharma LimitedPPLPHARMA · Market cap Rs 30,657 Cr
- Krishna Institute of Medical Sciences LimitedKIMS · Market cap Rs 29,505 Cr
- Granules India LimitedGRANULES · Market cap Rs 20,750 Cr
- Cohance Lifesciences LimitedCOHANCE · Market cap Rs 18,416 Cr
Companies are grouped mechanically from the exchange classification and listed by market capitalisation. This is a comparison set, not a ranking or recommendation.